Shilpa Medicare has launched a new full service ‘hybrid’ CDMO, which will see Shilpa serve both small and large molecules customers as well as peptides, with oncology as a particular therapeutic specialty.

In addition to offering comprehensive discovery, clinical, and commercial outsourcing services, Shilpa’s hybrid CDMO model also includes commercially ready ‘off-the-shelf’ novel formulations for exclusive b2b licensing. This dual approach enables pharmaceutical companies to leverage Shilpa’s extensive expertise in oncology without the direct risks and lengthy timelines associated with development.

The CDMO currently has multiple assets in its pipeline and three late-stage products available for licensing. Through this model, pharma companies can expedite their market entry by licensing fully developed products while still benefiting from Shilpa’s robust development and manufacturing capabilities.

Vishnukant C. Bhutada, Managing Director of Shilpa Medicare, commented: “Our goal is to offer pharmaceutical and biotech customers multiple flexible pathways to bring commercial products to market. On the one hand, they can leverage our development teams, cutting-edge technologies, and world-class facilities in a traditional CDMO partnership – with both our GLP-1 and biologics services in high demand at DCAT. On the other, we have a pipeline of fully developed products that are available for exclusive licensing, eliminating development risks for our partners. However, we remain strictly a b2b-only company, ensuring we never compete with our clients.”

Shilpa’s CDMO formulation services span oral solids, topicals, injectables, transdermal patches, ophthalmic delivery and oral thin films, while its manufacturing sites have approvals from global regulators including the FDA, EMA, PMDA, TGA and MHRA.